Literature DB >> 19152592

Corneal stromal invasive squamous cell carcinoma: a retrospective morphological description in 10 horses.

Christiane Kafarnik1, Melanie Rawlings, Richard R Dubielzig.   

Abstract

OBJECTIVE: To describe the pathomorphological features of corneal stromal invasive squamous cell carcinoma (CSI-SCC) in horses.
MATERIAL AND METHODS: A total of 87 equine SCC in the Comparative Ocular Pathology Laboratory of Wisconsin database were retrieved. The signalment and anatomical distribution were summarized. Ten CSI-SCC out of 87 SCCs were further investigated focusing on pathomorphological description. All 10 cases were stained with H&E, periodic acid-Schiff stain and Verhoeff's elastic stain.
RESULTS: Four Appaloosas, two Quarter horses, two American Paint, one Pinto and one Thoroughbred horse were affected. The mean age at the time of enucleation/keratectomy was 16.7 +/- 5.2 years. Out of 10, five horses were clinically diagnosed as chronic stromal keratitis, 3 of 10 had a previous biopsy diagnosed as SCC, 1 of 10 was described as stromal mass, and 1 of 10 as invasive SCC. Previous keratectomies before enucleation were performed in 3 of 10 horses, of which 2 also had additional lasertherapy/cryotherapy. Seven of 10 cases showed tumor infiltration in the anterior-mid stroma, 3/10 in the mid-deep stroma. The anterior epithelium had no contact with the CSI-SCC in 8 of 10 cases, 7 of 10 had intact and normal epithelium, and 3 of 10 showed intact, dysplastic corneal and conjunctival epithelium. The limbus was not pigmented in 8 of 10 specimens. There was a mild-moderate lymphoplasmacytic inflammation between the neoplastic islands. Solar elastosis was present in 2 of 10 samples.
CONCLUSION: The CSI-SCC shows a distinctive intrastromal tumor growth pattern with a smooth, intact corneal epithelium. The tumor can be underestimated and misdiagnosed as chronic active stromal keratitis. A deep biopsy is necessary for the definitive diagnosis.

Entities:  

Mesh:

Year:  2009        PMID: 19152592     DOI: 10.1111/j.1463-5224.2009.00666.x

Source DB:  PubMed          Journal:  Vet Ophthalmol        ISSN: 1463-5216            Impact factor:   1.644


  7 in total

1.  Diagnostic ophthalmology.

Authors:  Bruce H Grahn; Bianca S Bauer; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2014-07       Impact factor: 1.008

2.  Diagnostic Ophthalmology.

Authors:  Shayna Levitt; Stephanie Osinchuk; Lynne Sandmeyer
Journal:  Can Vet J       Date:  2020-07       Impact factor: 1.008

3.  A retrospective histologic study of 140 cases of clinically significant equine ocular disorders.

Authors:  Mariana M Flores; Fabio Del Piero; Perry L Habecker; Ingeborg M Langohr
Journal:  J Vet Diagn Invest       Date:  2020-03-24       Impact factor: 1.279

4.  Highly invasive and poorly differentiated corneal squamous cell carcinoma in a dog.

Authors:  López-Murcia María Del Mar; Mayordomo-Febrer Aloma; Viana David; Mozos Elena; Ortega Joaquín
Journal:  BMC Vet Res       Date:  2019-02-07       Impact factor: 2.741

5.  Additional Evidence for DDB2 T338M as a Genetic Risk Factor for Ocular Squamous Cell Carcinoma in Horses.

Authors:  Moriel H Singer-Berk; Kelly E Knickelbein; Zachary T Lounsberry; Margo Crausaz; Savanna Vig; Nikhil Joshi; Monica Britton; Matthew L Settles; Christopher M Reilly; Ellison Bentley; Catherine Nunnery; Ann Dwyer; Mary E Lassaline; Rebecca R Bellone
Journal:  Int J Genomics       Date:  2019-09-15       Impact factor: 2.326

6.  DDB2 Genetic Risk Factor for Ocular Squamous Cell Carcinoma Identified in Three Additional Horse Breeds.

Authors:  Margo Crausaz; Thomas Launois; Kathryn Smith-Fleming; Annette M McCoy; Kelly E Knickelbein; Rebecca R Bellone
Journal:  Genes (Basel)       Date:  2020-12-05       Impact factor: 4.096

7.  DNA methylation aging and transcriptomic studies in horses.

Authors:  Steve Horvath; Amin Haghani; Sichong Peng; Erin N Hales; Joseph A Zoller; Ken Raj; Brenda Larison; Todd R Robeck; Jessica L Petersen; Rebecca R Bellone; Carrie J Finno
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.